1. Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis 
Corey S. Miller, Alastair Dorreen, Myriam Martel, Thao Huynh, Alan N. Barkun 
Clinical Gastroenterology and Hepatology 
Volume 15, Issue 11, Pages e3 (November 2017)
DOI: /j.cgh
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1 Flowchart of the literature search and study selection.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

3. Figure 2
Forest plot of major gastrointestinal bleeding, non–vitamin k antagonist oral anticoagulant vs conventional therapy.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

4. Figure 3
Forest plot of major gastrointestinal bleeding by individual non–vitamin k antagonist oral anticoagulant. (A) Dabigatran vs conventional therapy. (B) Rivaroxaban vs conventional therapy.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

5. Figure 4
Forest plot of major gastrointestinal bleeding by individual non–vitamin k antagonist oral anticoagulant. (A) Apixaban vs conventional therapy. (B) Edoxaban vs conventional therapy.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Potential bias of included studies using the Cochrane Risk Bias Tool.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

7. Supplementary Figure 2
Forest plot of major gastrointestinal bleeding, novel oral anticoagulant vs conventional therapy, and hazard ratios. IV, instrumental variables.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions